Injection site reactions, thought to be the result of local mast cell degranulation, 40 were the most frequently reported adverse events in the SCF plus filgrastim group, occurring in 84% of patients.

Amgen sued Sandoz last October, alleging infringement of a patent on Neupogen, its $1.2 billion-a-year medicine that boosts white blood cell counts to fight infections in cancer patients.

Consensus estimates for Neupogen's U.S. sales already take into account competition from biosimilars and are forecast to drop to about $510 million in 2020 from $853.7 million in 2014, Evercore ...